A single arm, interventional study with 12 weeks study phase preceded by a 2-week run in phase, aiming to evaluate the effectiveness and applicability of the Tandem Mobi automated insulin delivery system (Tandem Mobi Pump System) for competitive youth athletes with type 1 diabetes in real-world conditions.
Type 1 diabetes (T1D) for at least 6 months
11≤Age≤18 years
HbA1c <10.0%
Current treatment with automated insulin delivery system (AID) or insulin pump for at least 1 month
Concomitant disease that influences metabolic control or HbA1c interpretation
Individual has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection)
Use of antidiabetic agents other than insulin
Two or more episodes of severe hypoglycemia (hypoglycemia requiring treatment by another person) within the previous 6 months